Inflammatory breast cancer and chest wall disease: The oncologist perspective

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Chest wall inflammatory and lymphangitic breast cancer represents a clinical spectrum and a model disease. Inflammation and the immune response have a role in the natural history of this special clinical presentation. Preclinical models and biomarker studies suggest that inflammatory breast cancer comprises a more important role for the tumour microenvironment, including immune cell infiltration and vasculogenesis, especially lympho-angiogenesis. Across this clinical continuum of the chest wall disease there is an important role of the inflammation cascade. The activation of mature dendritic cells (DCs) through toll like receptors (TLRs) or by inflammatory cytokines converts immature DCs into mature DCs that present specific antigen to T cells, thereby activating them. Maturation of DCs is accompanied by co-stimulatory molecules and secretion of inflammatory cytokines polarizing lymphocytic, macrophages and fibroblast infiltration. It is unknown whether immune cells associated to the IBC microenvironment play a role in this scenario to transiently promote epithelial to mesenchymal transition (EMT) in these cells. Immune and microenvirnment factors can induce phenotypic, morphological, and functional changes in breast cancer cells. We can hypothesize that similar inflammatory conditions in vivo may support both the rapid metastasis and tight tumor emboli that are characteristic of chest wall disease and that targeted anti-inflammatory therapy may play a role in this patient population. The current review will review biological and clinical data of this special condition.

Original languageEnglish
Pages (from-to)1142-1147
Number of pages6
JournalEuropean Journal of Surgical Oncology
Volume44
Issue number8
DOIs
Publication statusPublished - Aug 1 2018

Fingerprint

Inflammatory Breast Neoplasms
Thoracic Wall
Dendritic Cells
Play Therapy
Cytokines
Inflammation
Epithelial-Mesenchymal Transition
Tumor Microenvironment
Toll-Like Receptors
Immunologic Factors
Embolism
Natural History
Anti-Inflammatory Agents
Fibroblasts
Biomarkers
Macrophages
Breast Neoplasms
Neoplasm Metastasis
T-Lymphocytes
Antigens

Keywords

  • Chest wall disease
  • Inflammatory breast cancer

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Inflammatory breast cancer and chest wall disease : The oncologist perspective. / Curigliano, Giuseppe.

In: European Journal of Surgical Oncology, Vol. 44, No. 8, 01.08.2018, p. 1142-1147.

Research output: Contribution to journalReview article

@article{deef8b31bd774e2781f44f2e528a17e9,
title = "Inflammatory breast cancer and chest wall disease: The oncologist perspective",
abstract = "Chest wall inflammatory and lymphangitic breast cancer represents a clinical spectrum and a model disease. Inflammation and the immune response have a role in the natural history of this special clinical presentation. Preclinical models and biomarker studies suggest that inflammatory breast cancer comprises a more important role for the tumour microenvironment, including immune cell infiltration and vasculogenesis, especially lympho-angiogenesis. Across this clinical continuum of the chest wall disease there is an important role of the inflammation cascade. The activation of mature dendritic cells (DCs) through toll like receptors (TLRs) or by inflammatory cytokines converts immature DCs into mature DCs that present specific antigen to T cells, thereby activating them. Maturation of DCs is accompanied by co-stimulatory molecules and secretion of inflammatory cytokines polarizing lymphocytic, macrophages and fibroblast infiltration. It is unknown whether immune cells associated to the IBC microenvironment play a role in this scenario to transiently promote epithelial to mesenchymal transition (EMT) in these cells. Immune and microenvirnment factors can induce phenotypic, morphological, and functional changes in breast cancer cells. We can hypothesize that similar inflammatory conditions in vivo may support both the rapid metastasis and tight tumor emboli that are characteristic of chest wall disease and that targeted anti-inflammatory therapy may play a role in this patient population. The current review will review biological and clinical data of this special condition.",
keywords = "Chest wall disease, Inflammatory breast cancer",
author = "Giuseppe Curigliano",
year = "2018",
month = "8",
day = "1",
doi = "10.1016/j.ejso.2018.05.019",
language = "English",
volume = "44",
pages = "1142--1147",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "8",

}

TY - JOUR

T1 - Inflammatory breast cancer and chest wall disease

T2 - The oncologist perspective

AU - Curigliano, Giuseppe

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Chest wall inflammatory and lymphangitic breast cancer represents a clinical spectrum and a model disease. Inflammation and the immune response have a role in the natural history of this special clinical presentation. Preclinical models and biomarker studies suggest that inflammatory breast cancer comprises a more important role for the tumour microenvironment, including immune cell infiltration and vasculogenesis, especially lympho-angiogenesis. Across this clinical continuum of the chest wall disease there is an important role of the inflammation cascade. The activation of mature dendritic cells (DCs) through toll like receptors (TLRs) or by inflammatory cytokines converts immature DCs into mature DCs that present specific antigen to T cells, thereby activating them. Maturation of DCs is accompanied by co-stimulatory molecules and secretion of inflammatory cytokines polarizing lymphocytic, macrophages and fibroblast infiltration. It is unknown whether immune cells associated to the IBC microenvironment play a role in this scenario to transiently promote epithelial to mesenchymal transition (EMT) in these cells. Immune and microenvirnment factors can induce phenotypic, morphological, and functional changes in breast cancer cells. We can hypothesize that similar inflammatory conditions in vivo may support both the rapid metastasis and tight tumor emboli that are characteristic of chest wall disease and that targeted anti-inflammatory therapy may play a role in this patient population. The current review will review biological and clinical data of this special condition.

AB - Chest wall inflammatory and lymphangitic breast cancer represents a clinical spectrum and a model disease. Inflammation and the immune response have a role in the natural history of this special clinical presentation. Preclinical models and biomarker studies suggest that inflammatory breast cancer comprises a more important role for the tumour microenvironment, including immune cell infiltration and vasculogenesis, especially lympho-angiogenesis. Across this clinical continuum of the chest wall disease there is an important role of the inflammation cascade. The activation of mature dendritic cells (DCs) through toll like receptors (TLRs) or by inflammatory cytokines converts immature DCs into mature DCs that present specific antigen to T cells, thereby activating them. Maturation of DCs is accompanied by co-stimulatory molecules and secretion of inflammatory cytokines polarizing lymphocytic, macrophages and fibroblast infiltration. It is unknown whether immune cells associated to the IBC microenvironment play a role in this scenario to transiently promote epithelial to mesenchymal transition (EMT) in these cells. Immune and microenvirnment factors can induce phenotypic, morphological, and functional changes in breast cancer cells. We can hypothesize that similar inflammatory conditions in vivo may support both the rapid metastasis and tight tumor emboli that are characteristic of chest wall disease and that targeted anti-inflammatory therapy may play a role in this patient population. The current review will review biological and clinical data of this special condition.

KW - Chest wall disease

KW - Inflammatory breast cancer

UR - http://www.scopus.com/inward/record.url?scp=85049348541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049348541&partnerID=8YFLogxK

U2 - 10.1016/j.ejso.2018.05.019

DO - 10.1016/j.ejso.2018.05.019

M3 - Review article

C2 - 30032791

AN - SCOPUS:85049348541

VL - 44

SP - 1142

EP - 1147

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 8

ER -